[SCHEDULE 13G] Ascendis Pharma A/S American SEC Filing

Rhea-AI Filing Summary

Capital International Investors reported beneficial ownership of 3,109,225 shares of Ascendis Pharma A/S common stock, representing 5.6% of the 55,754,437 shares believed outstanding. The filing shows sole voting power for 3,099,512 shares and sole dispositive power for 3,109,225 shares. The shares reported are Depository Receipts that represent common stock. The filing classifies the filer as an investment adviser (IA) and includes a certification that the position is held in the ordinary course of business and not for the purpose of changing or influencing control.

Positive

• Institutional ownership of 5.6% (3,109,225 shares) signals meaningful investor interest
• Filer certifies passive intent (held in ordinary course and not to change or influence control)

Negative

• None.

Insights

Financial Analyst

TL;DR: Large passive institutional stake of 5.6% is disclosed; ownership is material but filed as passive under Schedule 13G.

The filing shows Capital International Investors holds 3,109,225 shares (5.6% of outstanding). For investors, an institutional holder of this size signals notable ownership concentration but, because the filer used Schedule 13G and certified the stake is held in the ordinary course and not to change control, it should be treated as passive. Voting and dispositive power figures are consistent with sole control over the position rather than shared management. Impact on governance or strategy is limited based on the filer's stated passive intent.

Corporate Governance Expert

TL;DR: 5.6% ownership by a recognized investment adviser is material; filing indicates no intent to influence control.

The Schedule 13G identifies Capital International Investors as an IA and discloses sole voting power for 3,099,512 shares and sole dispositive power for 3,109,225 shares. The certification explicitly states the securities were not acquired to change or influence issuer control, which aligns with a passive institutional holding. While the position is large enough to attract attention from proxy advisers or activist investors, the filing itself conveys no immediate governance actions or control intentions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ascendis Pharma AS

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04351P101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 04351P101

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,099,512.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,109,225.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,109,225.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ascendis Pharma AS
(b)	Address of issuer's principal executive offices: TUBORG BOULEVARD 12, HELLERUP, Denmark
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 04351P101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,109,225 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 3,109,225 shares or 5.6% of the 55,754,437 shares believed to be outstanding. Shares reported include 3,109,225 Depository Receipts, which represent 3,109,225 Common Stock.
(b)	Percent of class: 5.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,099,512
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,109,225
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	08/12/2025

FAQ

How many Ascendis Pharma (ASND) shares does Capital International Investors own?

Capital International Investors beneficially owns 3,109,225 shares, representing 5.6% of outstanding shares.

What voting and dispositive powers are reported by the filer for ASND?

The filer reports sole voting power for 3,099,512 shares and sole dispositive power for 3,109,225 shares.

Is the Schedule 13G filing for ASND filed as passive ownership?

Yes. The filing classifies the filer as an investment adviser (IA) and includes a certification that the position is held in the ordinary course of business and not to influence control.

How many shares outstanding does the filing reference for Ascendis (ASND)?

The filing states the position is 5.6% of 55,754,437 shares believed to be outstanding.

Does the filing indicate any group affiliation or shared control over the ASND position?

No. The filing indicates no shared voting or dispositive power and notes that group affiliation is not applicable.